tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Zymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating
PremiumRatingsZymeworks: Strong Financial Performance and Promising Pipeline Drive Buy Rating
16d ago
Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating
Premium
Ratings
Zymeworks’ Strategic Financial Management and Promising Pipeline Drive Buy Rating
16d ago
Zymeworks reports Q2 EPS 3c, consensus (46c)
Premium
The Fly
Zymeworks reports Q2 EPS 3c, consensus (46c)
16d ago
Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences
PremiumCompany AnnouncementsZymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences
1M ago
Positive Buy Rating for Zymeworks Amid Promising Clinical Trials and Strategic Partnerships
Premium
Ratings
Positive Buy Rating for Zymeworks Amid Promising Clinical Trials and Strategic Partnerships
2M ago
Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts
Premium
Ratings
Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts
2M ago
Zymeworks: Strategic Milestones and Promising Clinical Results Justify Buy Rating
PremiumRatingsZymeworks: Strategic Milestones and Promising Clinical Results Justify Buy Rating
3M ago
Zymeworks’ Zanidatamab: Promising Potential in HER2-Positive Cancer Treatment and Strategic Market Positioning Justify Buy Rating
Premium
Ratings
Zymeworks’ Zanidatamab: Promising Potential in HER2-Positive Cancer Treatment and Strategic Market Positioning Justify Buy Rating
3M ago
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer
Premium
Company Announcements
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100